Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Cancer: A Target Trial Emulation from SEER-Medicare Database
Cardiovascular Drugs and Therapy · 2025
DOI: 10.1007/s10557-024-07589-7 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cardiovascular Drugs and Therapy, 2025. Verfasst von Bang Truong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Outcomes Research and Policy, Auburn University Harrison College of Pharmacy, 4306d Walker Building, Auburn, AL, USA. Hauptthemen laut MEDLINE: Warfarin, Atrial Fibrillation, Anticoagulants, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
Direct oral anticoagulants (DOACs) are preferred over warfarin in patients with atrial fibrillation (AFib). However, their safety and effectiveness in patients with AFib and cancer are inconclusive.
Methods
We conducted a retrospective cohort study by emulating a target trial. Patients with a record of cancer (breast, prostate, or lung), newly diagnosed with AFib initiated DOACs or warfarin within 3 months after AFib diagnosis from the 2012–2019 Surveillance, Epidemiology, and End Results (SEER)-Medicare database were included. We compared the risk of ischemic stroke, major bleeding, and secondary outcomes (venous thromboembolism, intracranial bleeding, gastrointestinal bleeding, and non-critical site bleeding) between patients who initiated DOACs and warfarin. Inverse probability treatment weights and inverse probability censoring weights were used to adjust imbalanced patient and disease characteristics and loss to follow-up between the two groups. Weighted pooled logistic regression were used to estimate treatment effect with hazard ratios (HRs) with 95% confidence interval (95% CIs).
Results
The incidence rates of stroke and major bleeding between DOAC and warfarin initiators were 9.97 vs. 9.91 and 7.74 vs. 9.24 cases per 1000 person-years, respectively. In adjusted intention-to-treat analysis, patients initiated DOACs had no statistically significant difference in risk of ischemic stroke (HR = 0.87, 95% CI 0.52–1.44) and major bleeding (HR = 1.14, 95% CI 0.77–1.68) compared to those initiated warfarin. In adjusted per-protocol analysis, there was no statistical difference in risk of ischemic stroke (HR = 1.81, 95% CI 0.75–4.36) and lower risk for major bleeding, but the 95% CI was wide (HR = 0.35, 95% CI 0.12–0.99) among DOAC initiators compared to warfarin initiators. The benefits in secondary outcomes were in favor of DOACs. The findings remained consistent across subgroups and sensitivity analyses.
Conclusion
DOACs are safe and effective alternatives to warfarin in the management of patients with AFib and cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Outcomes Research and Policy, Auburn University Harrison College of Pharmacy, 4306d Walker Building, Auburn, AL, USA.
- Department of Pharmacy Practice, Auburn University Harrison College of Pharmacy, Auburn, AL, USA.
- Department of Mathematics and Statistics, Auburn University College of Sciences and Mathematics, Auburn, AL, USA.
- Department of Health Outcomes Research and Policy, Auburn University Harrison College of Pharmacy, 4306d Walker Building, Auburn, AL, USA. jzq0004@auburn.edu.
ORCID-Profile: Bang Truong, Jingjing Qian
Förderung
- NCI NIH HHS
Zitieren
APA
Truong, B., Hornsby, L., Fox, B., Chou, C., Zheng, J., & Qian, J. (2025). Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Cancer: A Target Trial Emulation from SEER-Medicare Database. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-024-07589-7
Vancouver
Truong B, Hornsby L, Fox B, Chou C, Zheng J, Qian J. Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Cancer: A Target Trial Emulation from SEER-Medicare Database. Cardiovascular Drugs and Therapy. 2025. doi:10.1007/s10557-024-07589-7
BibTeX
@article{Truong2025,
author = {Truong, Bang and Hornsby, Lori and Fox, Brent and Chou, Chiahung and Zheng, Jingyi and Qian, Jingjing},
title = {Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Cancer: A Target Trial Emulation from SEER-Medicare Database},
journal = {Cardiovascular Drugs and Therapy},
year = {2025},
doi = {10.1007/s10557-024-07589-7}
}
EUVIMED